Century Therapeutics Inc [IPSC] stock prices are up 2.02% to $0.56 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The IPSC shares have gain 12.76% over the last week, with a monthly amount glided 22.24%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Century Therapeutics Inc [NASDAQ: IPSC] stock has seen the most recent analyst activity on August 08, 2024, when Rodman & Renshaw initiated its Buy rating and assigned the stock a price target of $6. Previously, JP Morgan downgraded its rating to Neutral on August 28, 2023, and dropped its price target to $5. On December 27, 2022, Chardan Capital Markets initiated with a Buy rating and assigned a price target of $19 on the stock. Guggenheim started tracking the stock assigning a Buy rating and suggested a price target of $15 on October 31, 2022. Canaccord Genuity initiated its recommendation with a Buy and recommended $28 as its price target on October 10, 2022. H.C. Wainwright started tracking with a Buy rating for this stock on May 23, 2022, and assigned it a price target of $27. In a note dated May 12, 2022, William Blair initiated an Mkt Perform rating.
The stock price of Century Therapeutics Inc [IPSC] has been fluctuating between $0.34 and $3.70 over the past year. Currently, Wall Street analysts expect the stock to reach $5 within the next 12 months. Century Therapeutics Inc [NASDAQ: IPSC] shares were valued at $0.56 at the most recent close of the market. An investor can expect a potential return of 792.86% based on the average IPSC price forecast.
Analyzing the IPSC fundamentals
The Century Therapeutics Inc [NASDAQ:IPSC] reported sales of 6.59M for trailing twelve months, representing a surge of 1457.09%. Gross Profit Margin for this corporation currently stands at -1.02% with Operating Profit Margin at -21.08%, Pretax Profit Margin comes in at -18.93%, and Net Profit Margin reading is -19.21%. To continue investigating profitability, this company’s Return on Assets is posted at -0.36, Equity is -0.67 and Total Capital is -0.62. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.33.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.5482 points at the first support level, and at 0.5354 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.5712, and for the 2nd resistance point, it is at 0.5814.
Ratios To Look Out For
It’s worth pointing out that Century Therapeutics Inc [NASDAQ:IPSC]’s Current Ratio is 1.50. In addition, the Quick Ratio stands at 1.50 and the Cash Ratio stands at 0.45. Considering the valuation of this stock, the price to sales ratio is 7.34, the price to book ratio is 0.30.
Transactions by insiders
Recent insider trading involved Farid Adrienne, Officer, that happened on May 05 ’25 when 1024.0 shares were purchased. President and CEO, Pfeiffenberger Brent completed a deal on Mar 10 ’25 to sell 2235.0 shares. Meanwhile, Russotti Gregory sold 2360.0 shares on Mar 10 ’25.
